Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566712571> ?p ?o ?g. }
- W1566712571 endingPage "90" @default.
- W1566712571 startingPage "82" @default.
- W1566712571 abstract "SummaryBackground: Aspirin (ASA) + clopidogrel are commonly used in acute coronary syndrome (ACS), but persistent antiplatelet effects may complicate surgery.Methods and Results: To study the possibility of normalizing platelet reactivity after ASA + clopidogrel treatment, 11 healthy subjects received a 325‐mg ASA + clopidogrel loading dose (300 or 600 mg dependent on study arm), followed by 81 mg of ASA + 75 mg of clopidogrel daily for 2 days. Platelet reactivity was assessed by light transmittance aggregometry (LTA) [challenged by adenosine diphosphate (ADP), arachidonic acid (AA), collagen, and thrombin receptor activating peptide (TRAP)] and flow cytometry for platelet activation by GPIIb/IIIa receptor exposure pretreatment, 4 and 72 h postload. To normalize platelet reactivity, increasing amounts of pooled platelets from five untreated volunteers [volunteers (V)‐platelet‐rich plasma (PRP)] were added ex vivo to the subject's PRP (S‐PRP). At both 4 and 72 h, 40% and 50% V‐PRP were needed to overcome platelet disaggregation in the 300 or 600 mg arms, respectively, after ADP challenge; an additional 10% V‐PRP fully normalized aggregation. Recovery of function was linear with each incremental increase of V‐PRP. ADP‐induced GPIIb/IIIa activation showed the same pattern as LTA (r = 0.74). Forty percent V‐PRP was required to normalize platelet function to AA, collagen, and TRAP.Conclusion: Our results suggest that the pre‐operative transfusion of 10 platelet concentrate units (the equivalent of 40% V‐PRP) after a 300‐mg clopidogrel loading or 12.5 units (50% V‐PRP) after a 600 mg loading may adequately reverse clopidogrel‐induced platelet disaggregation to facilitate postoperative hemostasis. An additional 2.5 units fully normalized platelet function. The potential clinical implications of our observations could include shorter hospitalizations and reduced bleeding complications. But these observations should be fully explored in an in vivo clinical setting with clopidogrel‐treated patients before and after surgery. Background: Aspirin (ASA) + clopidogrel are commonly used in acute coronary syndrome (ACS), but persistent antiplatelet effects may complicate surgery.Methods and Results: To study the possibility of normalizing platelet reactivity after ASA + clopidogrel treatment, 11 healthy subjects received a 325‐mg ASA + clopidogrel loading dose (300 or 600 mg dependent on study arm), followed by 81 mg of ASA + 75 mg of clopidogrel daily for 2 days. Platelet reactivity was assessed by light transmittance aggregometry (LTA) [challenged by adenosine diphosphate (ADP), arachidonic acid (AA), collagen, and thrombin receptor activating peptide (TRAP)] and flow cytometry for platelet activation by GPIIb/IIIa receptor exposure pretreatment, 4 and 72 h postload. To normalize platelet reactivity, increasing amounts of pooled platelets from five untreated volunteers [volunteers (V)‐platelet‐rich plasma (PRP)] were added ex vivo to the subject's PRP (S‐PRP). At both 4 and 72 h, 40% and 50% V‐PRP were needed to overcome platelet disaggregation in the 300 or 600 mg arms, respectively, after ADP challenge; an additional 10% V‐PRP fully normalized aggregation. Recovery of function was linear with each incremental increase of V‐PRP. ADP‐induced GPIIb/IIIa activation showed the same pattern as LTA (r = 0.74). Forty percent V‐PRP was required to normalize platelet function to AA, collagen, and TRAP.Conclusion: Our results suggest that the pre‐operative transfusion of 10 platelet concentrate units (the equivalent of 40% V‐PRP) after a 300‐mg clopidogrel loading or 12.5 units (50% V‐PRP) after a 600 mg loading may adequately reverse clopidogrel‐induced platelet disaggregation to facilitate postoperative hemostasis. An additional 2.5 units fully normalized platelet function. The potential clinical implications of our observations could include shorter hospitalizations and reduced bleeding complications. But these observations should be fully explored in an in vivo clinical setting with clopidogrel‐treated patients before and after surgery." @default.
- W1566712571 created "2016-06-24" @default.
- W1566712571 creator A5023236388 @default.
- W1566712571 creator A5047668360 @default.
- W1566712571 creator A5073368003 @default.
- W1566712571 creator A5074727212 @default.
- W1566712571 creator A5079983244 @default.
- W1566712571 creator A5081257789 @default.
- W1566712571 creator A5090962770 @default.
- W1566712571 date "2007-01-01" @default.
- W1566712571 modified "2023-10-14" @default.
- W1566712571 title "Normalization of platelet reactivity in clopidogrel‐treated subjects" @default.
- W1566712571 cites W12076958 @default.
- W1566712571 cites W141287021 @default.
- W1566712571 cites W1553345686 @default.
- W1566712571 cites W182351055 @default.
- W1566712571 cites W1968545056 @default.
- W1566712571 cites W1971331535 @default.
- W1566712571 cites W1984396324 @default.
- W1566712571 cites W1991682502 @default.
- W1566712571 cites W1994676854 @default.
- W1566712571 cites W2005401250 @default.
- W1566712571 cites W2015977414 @default.
- W1566712571 cites W2030530220 @default.
- W1566712571 cites W2033851722 @default.
- W1566712571 cites W2041936661 @default.
- W1566712571 cites W2049832661 @default.
- W1566712571 cites W2058806563 @default.
- W1566712571 cites W2060554222 @default.
- W1566712571 cites W2085548132 @default.
- W1566712571 cites W2087103870 @default.
- W1566712571 cites W2090890063 @default.
- W1566712571 cites W2092331097 @default.
- W1566712571 cites W2096459479 @default.
- W1566712571 cites W2107797912 @default.
- W1566712571 cites W2118932793 @default.
- W1566712571 cites W2120097410 @default.
- W1566712571 cites W2121875473 @default.
- W1566712571 cites W2142107147 @default.
- W1566712571 cites W2156266070 @default.
- W1566712571 cites W2224057980 @default.
- W1566712571 cites W2254084468 @default.
- W1566712571 cites W2323661955 @default.
- W1566712571 cites W4213061012 @default.
- W1566712571 cites W4252057047 @default.
- W1566712571 doi "https://doi.org/10.1111/j.1538-7836.2006.02245.x" @default.
- W1566712571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17239165" @default.
- W1566712571 hasPublicationYear "2007" @default.
- W1566712571 type Work @default.
- W1566712571 sameAs 1566712571 @default.
- W1566712571 citedByCount "171" @default.
- W1566712571 countsByYear W15667125712012 @default.
- W1566712571 countsByYear W15667125712013 @default.
- W1566712571 countsByYear W15667125712014 @default.
- W1566712571 countsByYear W15667125712015 @default.
- W1566712571 countsByYear W15667125712016 @default.
- W1566712571 countsByYear W15667125712017 @default.
- W1566712571 countsByYear W15667125712018 @default.
- W1566712571 countsByYear W15667125712019 @default.
- W1566712571 countsByYear W15667125712020 @default.
- W1566712571 countsByYear W15667125712021 @default.
- W1566712571 countsByYear W15667125712022 @default.
- W1566712571 countsByYear W15667125712023 @default.
- W1566712571 crossrefType "journal-article" @default.
- W1566712571 hasAuthorship W1566712571A5023236388 @default.
- W1566712571 hasAuthorship W1566712571A5047668360 @default.
- W1566712571 hasAuthorship W1566712571A5073368003 @default.
- W1566712571 hasAuthorship W1566712571A5074727212 @default.
- W1566712571 hasAuthorship W1566712571A5079983244 @default.
- W1566712571 hasAuthorship W1566712571A5081257789 @default.
- W1566712571 hasAuthorship W1566712571A5090962770 @default.
- W1566712571 hasBestOaLocation W15667125711 @default.
- W1566712571 hasConcept C126322002 @default.
- W1566712571 hasConcept C181199279 @default.
- W1566712571 hasConcept C185592680 @default.
- W1566712571 hasConcept C202751555 @default.
- W1566712571 hasConcept C26291073 @default.
- W1566712571 hasConcept C2777292125 @default.
- W1566712571 hasConcept C2777399203 @default.
- W1566712571 hasConcept C2777628954 @default.
- W1566712571 hasConcept C2777849778 @default.
- W1566712571 hasConcept C2778078955 @default.
- W1566712571 hasConcept C2778905298 @default.
- W1566712571 hasConcept C2780076745 @default.
- W1566712571 hasConcept C2993802102 @default.
- W1566712571 hasConcept C3018697912 @default.
- W1566712571 hasConcept C55493867 @default.
- W1566712571 hasConcept C71924100 @default.
- W1566712571 hasConcept C89560881 @default.
- W1566712571 hasConcept C98274493 @default.
- W1566712571 hasConceptScore W1566712571C126322002 @default.
- W1566712571 hasConceptScore W1566712571C181199279 @default.
- W1566712571 hasConceptScore W1566712571C185592680 @default.
- W1566712571 hasConceptScore W1566712571C202751555 @default.
- W1566712571 hasConceptScore W1566712571C26291073 @default.
- W1566712571 hasConceptScore W1566712571C2777292125 @default.
- W1566712571 hasConceptScore W1566712571C2777399203 @default.
- W1566712571 hasConceptScore W1566712571C2777628954 @default.